[{"address1": "Building C14", "address2": "4th Floor No. 218, Xinghu Street Suzhou Industrial Park", "city": "Suzhou", "zip": "215123", "country": "China", "phone": "86 512 8777 3632", "website": "https://www.adagene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.", "fullTimeEmployees": 138, "companyOfficers": [{"maxAge": 1, "name": "Dr. Peter P.  Luo Ph.D.", "age": 58, "title": "Co- Founder, Chairman, CEO and President of R&D", "yearBorn": 1966, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Man Kin  Tam M.B.A.", "age": 47, "title": "CFO & Director", "yearBorn": 1977, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ling  Zhou", "title": "Executive Director & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Qinghai  Zhao Ph.D.", "age": 63, "title": "Chief Manufacturing Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yan  Li M.B.A.", "age": 49, "title": "Senior Vice President of Bioinformatics & Information Technology", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Xiaohong  She", "age": 57, "title": "Senior VP & Head of Clinical Operations", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Guizhong  Liu Ph.D.", "age": 53, "title": "Senior Vice President of Early Drug Discovery", "yearBorn": 1971, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Goergen", "age": 37, "title": "VP & Head of Business Development", "yearBorn": 1987, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jiping  Zha M.D., Ph.D.", "title": "Executive Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Songmao  Zheng Ph.D.", "title": "VP and Head of Clinical & Quantitative Pharmacology", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.46, "open": 1.45, "dayLow": 1.45, "dayHigh": 1.55, "regularMarketPreviousClose": 1.46, "regularMarketOpen": 1.45, "regularMarketDayLow": 1.45, "regularMarketDayHigh": 1.55, "payoutRatio": 0.0, "beta": 0.613, "forwardPE": -2.2173913, "volume": 5571, "regularMarketVolume": 5571, "averageVolume": 71026, "averageVolume10days": 26140, "averageDailyVolume10Day": 26140, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 72077688, "fiftyTwoWeekLow": 1.325, "fiftyTwoWeekHigh": 3.581, "priceToSalesTrailing12Months": 698.40015, "fiftyDayAverage": 1.80826, "twoHundredDayAverage": 2.27853, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 26375740, "profitMargins": 0.0, "floatShares": 23172601, "sharesOutstanding": 47109600, "sharesShort": 18307, "sharesShortPriorMonth": 40125, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.0763, "heldPercentInstitutions": 0.3062, "shortRatio": 0.63, "shortPercentOfFloat": 0.0005, "impliedSharesOutstanding": 47780100, "bookValue": 1.072, "priceToBook": 1.4272387, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -33424112, "trailingEps": -0.74, "forwardEps": -0.69, "enterpriseToRevenue": 255.569, "enterpriseToEbitda": -0.749, "52WeekChange": -0.41153848, "SandP52WeekChange": 0.059571505, "quoteType": "EQUITY", "currentPrice": 1.53, "targetHighPrice": 19.06, "targetLowPrice": 3.5, "targetMeanPrice": 10.18667, "targetMedianPrice": 8.0, "recommendationMean": 2.25, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 85194504, "totalCashPerShare": 1.447, "ebitda": -35228592, "totalDebt": 18493540, "quickRatio": 2.231, "currentRatio": 2.299, "totalRevenue": 103204, "debtToEquity": 36.604, "revenuePerShare": 0.002, "returnOnAssets": -0.21922001, "returnOnEquity": -0.55208, "grossProfits": 103204, "freeCashflow": -18872740, "operatingCashflow": -29700984, "revenueGrowth": -0.873, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -170.82393, "financialCurrency": "USD", "symbol": "ADAG", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Adagene Inc.", "longName": "Adagene Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": -0.64935, "postMarketPrice": 1.53, "postMarketChange": -0.00999999, "regularMarketChange": 0.06999993, "regularMarketDayRange": "1.45 - 1.55", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 71026, "fiftyTwoWeekLowChange": 0.20499992, "fiftyTwoWeekLowChangePercent": 0.15471692, "fiftyTwoWeekRange": "1.325 - 3.581", "fiftyTwoWeekHighChange": -2.051, "fiftyTwoWeekHighChangePercent": -0.5727451, "fiftyTwoWeekChangePercent": -41.153847, "earningsTimestamp": 1742817602, "earningsTimestampStart": 1742817602, "earningsTimestampEnd": 1742817602, "isEarningsDateEstimate": false, "corporateActions": [], "postMarketTime": 1744401911, "regularMarketTime": 1744401600, "epsTrailingTwelveMonths": -0.74, "epsForward": -0.69, "epsCurrentYear": -0.83, "priceEpsCurrentYear": -1.8433735, "fiftyDayAverageChange": -0.27826, "fiftyDayAverageChangePercent": -0.15388274, "twoHundredDayAverageChange": -0.7485299, "twoHundredDayAverageChangePercent": -0.32851443, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-02-09", "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "exchange": "NGM", "messageBoardId": "finmb_118162960", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 4.7945156, "regularMarketPrice": 1.53, "displayName": "Adagene", "trailingPegRatio": null, "__fetch_time": "2025-04-12"}]